Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBP
Overview | Financials
Company Name | Corbus Pharmaceuticals Holdings, Inc. |
Symbol | CRBP |
Currency | USD |
Price | 12.75 |
Market Cap | 155,288,625 |
Dividend Yield | 0% |
52-week-range | 5.665 - 61.9 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Yuval Cohen Ph.D. |
Website | https://www.corbuspharma.com |
An error occurred while fetching data.
About Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD